By Barbara Obstoj-Cardwell. Editor
Cash-rich since its $40.5 billion sale of its generics business to Teva Pharmaceutical Industries, Ireland -incorporated Allergan was on the takeover trial again last week, announcing two acquisitions, - Arkana Therapeutics and Tobira Therapeutics - making its total buys in the year to date seven.
Once again, Allergan proved that there’s no premium too big when it has identified a company it wants to purchase, according to Ben Levisohn in an article for Barron’s magazine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze